ATE370960T1 - Verknüpfte peptid-nukleinsäuren - Google Patents

Verknüpfte peptid-nukleinsäuren

Info

Publication number
ATE370960T1
ATE370960T1 AT95928084T AT95928084T ATE370960T1 AT E370960 T1 ATE370960 T1 AT E370960T1 AT 95928084 T AT95928084 T AT 95928084T AT 95928084 T AT95928084 T AT 95928084T AT E370960 T1 ATE370960 T1 AT E370960T1
Authority
AT
Austria
Prior art keywords
peptide nucleic
nucleic acids
strands
peptide
pyrimidines
Prior art date
Application number
AT95928084T
Other languages
English (en)
Inventor
Michael Egholm
Peter Nielsen
Ole Buchardt
Kim Dueholm
Leif Christensen
James Coull
John Kiely
Michael Griffith
Original Assignee
Isis Pharmaceuticals Inc
Perseptive Biosystems Inc
Buchardt Dorte
Michael Egholm
Nielsen Peter Eigil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Perseptive Biosystems Inc, Buchardt Dorte, Michael Egholm, Nielsen Peter Eigil filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE370960T1 publication Critical patent/ATE370960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95928084T 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren ATE370960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/275,951 US6451968B1 (en) 1991-05-24 1994-07-15 Peptide nucleic acids

Publications (1)

Publication Number Publication Date
ATE370960T1 true ATE370960T1 (de) 2007-09-15

Family

ID=23054499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928084T ATE370960T1 (de) 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren

Country Status (7)

Country Link
US (1) US6451968B1 (de)
EP (1) EP0773950B1 (de)
JP (1) JP3326181B2 (de)
AT (1) ATE370960T1 (de)
AU (1) AU3196795A (de)
DE (1) DE69535575D1 (de)
WO (1) WO1996002558A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105286A1 (en) * 1991-05-24 2003-06-05 Michael Egholm Linked peptide nucleic acids
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
JP4034351B2 (ja) 1996-04-25 2008-01-16 バイオアレイ ソリューションズ エルエルシー 粒子近接表面の光制御した動電学的アッセンブリ
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US6300318B1 (en) * 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
ATE478090T1 (de) 1997-10-27 2010-09-15 Boston Probes Inc SICH AUF ßPNA MOLECULAR BEACONSß BEZIEHENDE VERFAHREN, TESTSÄTZE UND ZUSAMMENSETZUNGEN
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
WO1999055914A1 (en) 1998-04-29 1999-11-04 Trustees Of Boston University Methods and compositions pertaining to pd-loops
GB9815933D0 (en) * 1998-07-23 1998-09-23 Secr Defence Detection method
JP2003511466A (ja) * 1998-11-11 2003-03-25 パンセコ・アクティーゼルスカブ 修飾ｐｎａ分子
US6548651B1 (en) * 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
EP1292606A4 (de) * 2000-06-23 2004-03-24 Yissum Res Dev Co Positiv geladene peptidische nukleinsäureanaloga mit verbesserten eigenschaften
EP1412517B1 (de) 2001-03-09 2006-11-29 Boston Probes, Inc. Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
EP1463825B1 (de) 2001-10-15 2017-12-06 BioArray Solutions Ltd. Gemultiplexte analyse polymorphischer stellen durch gleichzeitige abfrage und enzymvermittelte detektion
US7041453B2 (en) * 2002-08-22 2006-05-09 Bioarray Solutions Ltd. Molecular constructs and methods of use for detection of biochemical reactions
US7526114B2 (en) 2002-11-15 2009-04-28 Bioarray Solutions Ltd. Analysis, secure access to, and transmission of array images
DE602004030114D1 (de) * 2003-05-20 2010-12-30 Investigen Inc System zum nachweis von polynukleotiden
CA2539824C (en) 2003-09-22 2015-02-03 Xinwen Wang Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung
CA2899287A1 (en) 2003-10-28 2005-05-12 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US7543412B2 (en) * 2004-06-14 2009-06-09 Haworth, Ltd. Wall panel edge rail connector arrangement
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7306785B2 (en) * 2004-09-23 2007-12-11 General Electric Company Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
JP5479731B2 (ja) 2005-06-02 2014-04-23 アドヴァンディーエックス，インコーポレイテッド 微生物を解析するためのペプチド核酸プローブ
US20100041738A1 (en) 2005-06-20 2010-02-18 Avaris Ab Hybridization-stabilizing construct
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2007100711A2 (en) * 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
EP3305915B1 (de) 2006-08-01 2022-01-26 Applied Biosystems, LLC Nachweis von analyten und nukleinsäuren
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
WO2008072933A1 (en) * 2006-12-15 2008-06-19 Panagene Inc. Peptide nucleic acids conjugated with multi -amine linkers and nucleic acid detecting device using the same
WO2008103702A2 (en) 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US7964355B2 (en) * 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
EP2462230B1 (de) * 2009-08-03 2015-07-15 Recombinetics, Inc. Verfahren und zusammensetzungen für gezielte genmodifikation
CN108456211A (zh) * 2009-10-16 2018-08-28 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
NZ599290A (en) 2009-10-16 2014-10-31 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
US20140170653A1 (en) 2011-04-15 2014-06-19 Life Technologies Corporation Chemical ligation
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3038623A4 (de) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimikrobielle verbindungen und verfahren zur herstellung und verwendung davon
MA39171A1 (fr) 2014-01-10 2017-07-31 Glaxosmithkline Intellectual Property (No 2) Ltd Dérivés d'hydroxy formamide et leur utilisation
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3633047B1 (de) 2014-08-19 2022-12-28 Pacific Biosciences of California, Inc. Verfahren zur sequenzierung von nukleinsäuren basierend auf einer anreicherung von nukleinsäuren
HK1249758A1 (zh) 2015-03-11 2018-11-09 Melinta Therapeutics, Inc. 抗微生物化合物及其制备和使用方法
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0433345B1 (de) 1988-09-01 1994-04-20 Forskningscenter Riso Peptid-synthese und fester träger zur verwendung dabei
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
FI940922A7 (fi) 1991-08-30 1994-04-07 Univ Johns Hopkins Kolmoiskierukkakompleksien muodostus kaksijuosteisesta DNA:sta käyttäe n nukleosidioligomeereja, jotka sisältävät puriiniemäsanalogeja
MX9207334A (es) 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
WO1993018187A1 (en) 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
AU4846793A (en) 1992-09-04 1994-03-29 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
JPH08504103A (ja) 1992-12-08 1996-05-07 ジンタ・インコーポレイテッド 新しいモチーフを用いた３重らせん複合体の形成

Also Published As

Publication number Publication date
EP0773950B1 (de) 2007-08-22
EP0773950A1 (de) 1997-05-21
DE69535575D1 (de) 2007-10-04
US6451968B1 (en) 2002-09-17
JP3326181B2 (ja) 2002-09-17
JPH10503759A (ja) 1998-04-07
AU3196795A (en) 1996-02-16
EP0773950A4 (de) 2000-05-17
WO1996002558A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
ATE370960T1 (de) Verknüpfte peptid-nukleinsäuren
FI953743A0 (fi) Keratolyyttistä ja/tai finnitaudinvastaista aktiivisuutta omaavia kosmeettisia koostumuksia, niiden valmistus ja käyttö
FI956019L (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
DK1029870T3 (da) Hybride immunglobuliner til anvendelse i terapeutiske fremgangsmåder
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
ATE515569T1 (de) Peptidnucleinsäuren
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
ATE391789T1 (de) Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
FI965201A7 (fi) Puhdistetut Polyporus-lakkaasit ja niitä koodaavat nukleiinihapot
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
EP0585257A4 (de) Für natürliche killerzellen spezifische dna- und aminosäuresequenz.
DK0705846T3 (da) Höjmolekylære og lavmolekylære fraktioner af von Willebrand-faktor
ATE387458T1 (de) Fas-antigenbindender ligand
ATE311402T1 (de) Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
FI972703L (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ATE222264T1 (de) Multimerische mehrzweckwirkstoffe gegen thrombose
FR2611736B1 (fr) Nouveaux complexes chromiferes 1:2, leur preparation et leur utilisation comme colorants
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
SE9602822D0 (sv) New receptor
EA200000567A1 (ru) Бактериальные плазмиды
FR2692903B1 (fr) Nouveaux complexes metalliferes 1:2 asymetriques, leur preparation et leur utilisation comme colorants anioniques.
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
EP0237676A3 (de) Rekombinantes Ricin-Toxin
IE860922L (en) Hair waving compositions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties